Therefore, when injectable therapy is needed, most clinical practice recommendations, including the very recent American Diabetes Association guideline in 2022, suggest GLP-1 RA is preferred to insulin based on its additional benefits in body weight and organ protection [10]. The gene discussed is INS; the disease is diabetes mellitus.